Entrada Therapeutics Announces Closing of Initial Public Offering
Entrada Therapeutics, Inc. (TRDA)
Company Research
Source: GlobeNewswire
BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients by establishing Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines and aiming to become the world’s foremost intracellular therapeutics company, today announced the closing of its initial public offering of 9,075,000 shares of common stock, at a price to the public of $20.00 per share. All shares were offered by Entrada. The gross proceeds to Entrada from the offering, before deducting underwriting discounts, commissions and other offering expenses, were approximately $181.5 million. The shares began trading on The Nasdaq Global Market under the ticker symbol “TRDA” on October 29, 2021. In addition, the underwriters have a 30-day option to purchase up to an additional 1,361,250 shares of common stock at the initial public offering price less underwriting discounts and commissions. Goldman Sachs & Co. LLC, Cowen
Show less
Read more
Impact Snapshot
Event Time:
TRDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TRDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TRDA alerts
High impacting Entrada Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TRDA
News
- The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.PR Web
- Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates [Yahoo! Finance]Yahoo! Finance
- Entrada Therapeutics, Inc. (NASDAQ: TRDA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Entrada Therapeutics to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
TRDA
Earnings
- 3/13/24 - Miss
TRDA
Analyst Actions
- 3/18/24 - HC Wainwright
TRDA
Sec Filings
- 4/24/24 - Form 144
- 4/23/24 - Form 144
- 4/19/24 - Form 144
- TRDA's page on the SEC website